Successful treatment with intravenous immunoglobulins in a patient affected by dermatomyositis/systemic lupus erythematosus overlap syndrome and tuberculosis.
The case of a 56-year-old woman, with a previous history of systemic lupus erythematosus (SLE), later diagnosed as also affected by active dermatomyositis (DM) associated with tuberculosis (TB) is reported. Since TB is a contra-indication to receive immunosuppressive therapy for DM/SLE, intravenous immunoglobulins (IVIG) with low-dose steroids and anti-TB therapy were administered with excellent clinical results. This report underlines the crucial role of IVIG in the treatment of critical patients suffering from connective tissue disorders associated with severe infections.
Luzi
Giuseppe
G
Sapienza University of Rome, 2nd School of Medicine, S. Andrea University Hospital, Department of Medical Sciences, Via di Grottarossa 1039, 00189 Roma, Italy.
Diamanti
Andrea Picchianti
AP
Germano
Valentina
V
Laganà
Bruno
B
Di Rosa
Roberta
R
Salemi
Simonetta
S
Stoppacciaro
Antonella
A
D'Amelio
Raffaele
R
D000995:Antitubercular Agents / Q000627:therapeutic use; D003882:Dermatomyositis / Q000150:complications / Q000382:microbiology / Q000628:therapy*; D005260:Female; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000627:therapeutic use*; D007538:Isoniazid / Q000627:therapeutic use; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000382:microbiology / Q000628:therapy*; D008875:Middle Aged; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D014376:Tuberculosis / Q000150:complications / Q000188:drug therapy / Q000628:therapy*
D000995:Antitubercular Agents; D016756:Immunoglobulins, Intravenous; D007155:Immunologic Factors; D011718:Pyrazinamide; D007538:Isoniazid; D012293:Rifampin